Genmab ADR [GMAB] stock prices are up 0.21% to $28.35 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The GMAB shares have gain 0.78% over the last week, with a monthly amount glided 13.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on July 15, 2024, when RBC Capital Mkts upgraded its rating to a Outperform. Previously, BMO Capital Markets upgraded its rating to Outperform on February 23, 2024, and elevated its price target to $48. On January 22, 2024, downgrade downgraded it’s rating to Sell. UBS upgraded its rating to a Buy. Deutsche Bank upgraded its rating to a Buy. DNB Markets upgraded its rating to Buy for this stock on November 08, 2023. In a note dated October 18, 2023, Exane BNP Paribas initiated an Underperform rating.
The stock price of Genmab ADR [GMAB] has been fluctuating between $24.53 and $40.68 over the past year. Currently, Wall Street analysts expect the stock to reach $43.71 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $28.35 at the most recent close of the market. An investor can expect a potential return of 54.18% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
The Genmab ADR [NASDAQ:GMAB] reported sales of 2.58B for trailing twelve months, representing a surge of 46.59%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.4%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.18 and Total Capital is 0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.25 points at the first support level, and at 28.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.49, and for the 2nd resistance point, it is at 28.64.
Ratios To Look Out For
It’s worth pointing out that Genmab ADR [NASDAQ:GMAB]’s Current Ratio is 12.46. On the other hand, the Quick Ratio is 12.42, and the Cash Ratio is 5.32. Considering the valuation of this stock, the price to sales ratio is 7.15, the price to book ratio is 3.92 and price to earnings (TTM) ratio is 23.51.
